Wikipedia -WSS

Wikipedia

author：comprehensive 2025-10-01 21:35:21 - browse：77637

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： The real point of Kenneth Smith’s execution by nitrogen gas

WSS

FDA drug safety: Singulair case shows systemic surveillance flaws

FDA drug safety: Singulair case shows systemic surveillance flaws

NYU radiologists take on the challenge of expensive MRI machines

FDA's Woodcock to retire early next year

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

leisure time

Wikipedia

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

After affirmative action ruling, medical educators look to 'holistic review'

Quicker fix for pulse oximeters urged during FDA public meeting

New air purifier tech could be key to improving indoor air quality

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Hepatitis C has a cure — but many Americans still lack access to it

General Catalyst, Summa Health deal will turn on physician buy

hotspot

FDA drug safety: Singulair case shows systemic surveillance flaws

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Covid misinformation case heads to Supreme Court

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Biden administration opens offers in Medicare drug price negotiations

Vertigo drug brings hope for rare neuron disorder, Niemann

leisure time

entertainment

leisure time

focus